Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Amortization (2020 - 2022)

Historic Amortization for Mereo BioPharma (MREO) over the last 3 years, with Q2 2022 value amounting to $103.0 million.

  • Mereo BioPharma's Amortization fell 3875.02% to $103.0 million in Q2 2022 from the same period last year, while for Jun 2022 it was $103.0 million, marking a year-over-year decrease of 3875.02%. This contributed to the annual value of $133.9 million for FY2021, which is 5033.62% up from last year.
  • As of Q2 2022, Mereo BioPharma's Amortization stood at $103.0 million, which was down 3875.02% from $133.9 million recorded in Q4 2021.
  • Over the past 5 years, Mereo BioPharma's Amortization peaked at $168.2 million during Q2 2021, and registered a low of $82.8 million during Q2 2020.
  • Moreover, its 3-year median value for Amortization was $103.0 million (2022), whereas its average is $115.9 million.
  • Its Amortization has fluctuated over the past 5 years, first skyrocketed by 10314.09% in 2021, then tumbled by 3875.02% in 2022.
  • Mereo BioPharma's Amortization (Quarter) stood at $91.6 million in 2020, then soared by 46.2% to $133.9 million in 2021, then dropped by 23.06% to $103.0 million in 2022.
  • Its Amortization was $103.0 million in Q2 2022, compared to $133.9 million in Q4 2021 and $168.2 million in Q2 2021.